HDAC-dependent ventricular remodeling.

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Epigenetics

Background:

• Heart failure is a prevalent condition with high morbidity and mortality, despite current therapies.
• Pathological cardiac remodeling, driven by stress, leads to myocardial injury and heart failure.
• Reversible protein acetylation, regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), plays a key role in biological processes, including cardiac remodeling.

Purpose of the Study:

• To investigate the therapeutic potential of HDAC inhibitors in mitigating pathological cardiac remodeling and preventing heart failure.
• To elucidate the mechanisms by which HDAC inhibitors affect cardiac stress responses.

Main Methods:

• Utilized models of pressure overload and ischemia/reperfusion to induce pathological cardiac remodeling.
• Administered HDAC inhibitors to assess their impact on cardiac structure and function.
• Examined molecular mechanisms including cardiomyocyte death, hypertrophy, and ventricular fibrosis.

Main Results:

• HDAC inhibitors effectively blunted pathological cardiac remodeling in response to pressure overload and ischemia/reperfusion.
• HDAC inhibition reduced stress-induced cardiomyocyte death, hypertrophy, and ventricular fibrosis.
• These effects collectively diminish the emergence and progression of heart failure.

Conclusions:

• HDAC inhibitors represent a promising novel therapeutic strategy for heart failure.
• Targeting HDACs may arrest the adverse consequences of pathological cardiac stress.
• This approach holds potential clinical benefit for millions of heart failure patients.